Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole and Anlotinib in Platinum-resistant Recurrent Ovarian Cancer
NCT04720807Phase 2Unknown
- Sponsor
- Xinhua Hospital
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Xinhua Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04720807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720807.